News & Updates

The human monoclonal antibody pamrevlumab fails to deliver benefit for patients with idiopathic pulmonary fibrosis (IPF) in the phase III ZEPHYRUS-1 trial.

Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.

The phase III NOTUS trial further validates the potential of the monoclonal antibody dupilumab in reducing exacerbations and improving lung function and quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.